Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799828 | 0.96 | DPP7 (0.50) | MAPTHSD17B10EPHX2DPP7MEN1 | |
| SCHEMBL23807034 | 0.95 | EPHX1 (0.50) | EPHX2DPP7ACHETSHRMMP8 | |
| SCHEMBL12543410 | 0.95 | MAPT (0.55) | MAPTHSD17B10DPP7MEN1KMT2A | |
| SCHEMBL22794783 | 0.93 | MMP8 (0.49) | MAPTDPP7MEN1KMT2AACHE | |
| SCHEMBL21107013 | 0.93 | MMP8 (0.49) | MAPTDPP7MEN1KMT2AACHE | |
| SCHEMBL22837672 | 0.93 | MEN1 (0.55) | MAPTHSD17B10EPHX2DPP7MEN1 | |
| SCHEMBL23696456 | 0.91 | MEN1 (0.58) | MAPTHSD17B10EPHX2DPP7MEN1 | |
| SCHEMBL22837704 | 0.91 | MEN1 (0.58) | MAPTHSD17B10EPHX2DPP7MEN1 | |
| SCHEMBL22856581 | 0.91 | MEN1 (0.58) | MAPTHSD17B10EPHX2DPP7MEN1 | |
| SCHEMBL12543137 | 0.91 | MAPT (0.48) | MAPTHSD17B10EPHX2DPP7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023077077-A1 | RNA DEGRADERS AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | MAPT 258/4885HSD17B10 1154/4885EPHX2 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.